Paul Tudor Jones Dexcom Inc Call Options Transaction History

Tudor Investment Corp Et Al

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$110.31 - $140.45 $529,488 - $674,160	-4,800 Reduced 66.67%	2,400 $272,000
Q1 2024 May 15, 2024	SELL	$114.22 - $140.1 $765,274 - $938,670	-6,700 Reduced 48.2%	7,200 $998,000
Q4 2023 Feb 14, 2024	SELL	$75.49 - $124.16 $317,058 - $521,472	-4,200 Reduced 23.2%	13,900 $1.72 Million
Q3 2023 Nov 15, 2023	BUY	$86.06 - $137.93 $1.18 Million - $1.89 Million	13,700 Added 311.36%	18,100 $1.69 Million
Q2 2023 Aug 14, 2023	BUY	$112.47 - $130.98 $494,868 - $576,312	4,400 New	4,400 $565,000
Q4 2022 Feb 14, 2023	BUY	$84.98 - $122.67 $832,804 - $1.2 Million	9,800 New	9,800 $1.11 Million
Q2 2022 Aug 15, 2022	BUY	$67.99 - $132.89 $414,738 - $810,628	6,100 New	6,100 $453,000

1,013

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $29.5B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.